An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Forma Therapeutics, a clinical-stage biopharmaceutical company, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 7:30 a.m. EST. The company focuses on developing therapeutics for sickle cell disease, prostate cancer, and other rare hematologic diseases. A webcast of the presentation will be available on their website. Forma aims to transform patient lives by creating drug candidates that address high unmet needs, leveraging deep biological insight and clinical development expertise.
Positive
None.
Negative
None.
WATERTOWN, Mass.--(BUSINESS WIRE)--
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Jan. 13, 2022 at 7:30 a.m. Eastern Standard Time (EST).
A webcast of the conference presentation will be available in the “News & Investors” section of Forma’s website at www.FormaTherapeutics.com.
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. For more information, please visit www.FormaTherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.
